Aldeyra Therapeutics, headquartered in Lexington, Mass., announced positive data from a clinical trial of its topical NS2 to treat skin conditions caused by Sjogren-Larsson Syndrome (SLS).
Japan’s Eisai Co. said the U.S. FDA had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer’s disease.
AstraZeneca’s cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.
Mesoblast Ltd. said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines.
So far, at the Olympics many feared would be the Zika Games, so good. With as many as one million people expected to attend the spectacle – half of them foreigners – Rio de Janeiro has not turned out to be the Zika hothouse some athletes and visitors feared as the virus wreaked havoc in Brazil earlier in 2016.
Leadership today equals leading, managing and constantly adapting to change. Here are some steps to get on a path to change and engage your organization.
Scientists have found a single class of drugs that can kill the parasites responsible for three tropical diseases that affect millions in Africa, Asia and Latin America.
A cardiologist running a clinical trial for Bay Area’s Regado Biosciences has been indicted by a grand jury on two charges of alleged securities fraud, StatNews reported.
Shares of Ono Pharmaceutical were down nearly 20 percent in Monday’s trading after a Phase III trial for the lung cancer treatment Opdivo that it was co-developing with Bristol-Myers Squibb failed to meet its endpoints.